CAS: 1821370-28-8

MitoPQ (MitoParaquat) inhibits insulin-stimulated glucose uptake and plasma membrane translocation in myotubes and can be used to study oxidative stress.

Mitopq is a novel mitochondrial-targeting compound, which is synthesized through advanced biochemical engineering, designed to localize specifically within the mitochondria of eukaryotic cells. Its source is rooted in sophisticated organic synthesis techniques that allow for precision delivery and targeted engagement with mitochondrial components. This compound operates by selectively entering the mitochondria and interacting with the mitochondrial membrane and matrix. Its mode of action involves modulating mitochondrial bioenergetics and enhancing the efficiency of oxidative phosphorylation, thereby optimizing ATP production while limiting excessive reactive oxygen species (ROS) generation. As a result, Mitopq may help in maintaining cellular homeostasis and vitality. Mitopq is primarily utilized in experimental and clinical settings to investigate and manipulate mitochondrial function. It finds applications in studies related to mitochondrial dysfunction, aging, and metabolic diseases. Researchers employ Mitopq to explore pathways involved in cellular energy metabolism and to assess potential therapeutic strategies for conditions driven by mitochondrial deficits. It serves as a crucial tool for scientists aiming to elucidate the complex interplay between mitochondria and cellular health.

MitoPQ